Vor Biopharma Q4 profit tops estimates on warrant fair value gain

Reuters03-30
<a href="https://laohu8.com/S/VOR">Vor Biopharma</a> Q4 profit tops estimates on warrant fair value gain

Overview

  • US biotech firm's Q4 net income beat analyst expectations, driven by warrant fair value changes

  • Company completed $75 mln private placement, boosting pro-forma cash to $530.2 mln

  • Q4 R&D expenses fell on lower headcount, G&A expenses rose on higher compensation and services

Outlook

  • Vor Bio anticipates topline data from myasthenia gravis trial in 1H 2027

  • Company expects pro-forma cash balance to fund operations into early 2029

  • Vor Bio advancing telitacicept for potential regulatory approvals in US, Europe, Japan

Result Drivers

  • WARRANT FAIR VALUE - Net income increase in Q4 was primarily due to gain on change in fair value of outstanding liability-classified warrants

  • R&D SPENDING SHIFT - Q4 R&D expenses decreased due to lower headcount and reduced spend on previous programs, partially offset by increased spend on telitacicept programs

  • G&A COST INCREASE - Q4 G&A expenses rose due to higher stock-based compensation, personnel costs and professional service costs

Company press release: ID:nGNX3Yy11h

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Net Income

Beat

$1.72 bln

-$28.88 mln (7 Analysts)

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Vor Biopharma Inc is $43.00, about 197% above its March 27 closing price of $14.48

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment